News

As part of the agreement, the collaboration will sponsor a variety of research projects by granting funds to support proposals selected by a joint research committee. The funds

GSK plans to use the data for global regulatory submissions for its investigational glucagon-like peptide-1 (GLP-1) receptor agonist albiglutide to treat type 2 diabetes in early 2013. The

The company said APF530 drug candidate is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. The US Patent application No. 13/279,949 and

Omeclamox-Pak, a ten-day, triple combination oral therapy, is comprised of omeprazole delayed-release capsules (20mg), clarithromycin tablets (500mg) and amoxicillin capsules (500mg). Pernix president and chief executive officer Cooper

The orphan drug designation provides substantial potential benefits to the sponsor, including funding for certain clinical studies, study-design assistance, tax incentives and seven years of market exclusivity for

The new license will allow the pharmaceutical company to deploy the technology broadly throughout its organization and provide for long-term access. As a part of the agreement, the

Governor Anatoly Artamonov announced that the hub will start with six residents Denmark’s Novo Nordisk, British-Swedish AstraZeneca, Germany’s Stada and Italy’s Menarini, as well as domestic drug makers

Under the collaboration, Inova Software will link components of its Inova Suite with EBD’s partneringONE system, which generates more than 40,000 one-to-one meetings at EBD group’s six life

Regnite, which was discovered by XenoPort, is dosed once-daily and delivers a new chemical entity that utilizes naturally-occurring, nutrient transporters in the gastrointestinal tract to achieve efficient absorption